Quantcast

Latest Glutamate carboxypeptidase II Stories

2013-03-07 23:46:14

Adding supplements to antipsychotic medication alleviated negative symptoms in patients with specific gene variants Adding the dietary supplements folate and vitamin B12 to treatment with antipsychotic medication improved a core symptom component of schizophrenia in a study of more than 100 patients. The study focused on negative symptoms of schizophrenia — which include apathy, social withdrawal, and a lack of emotional expressiveness. While the level of improvement across all...

2012-11-20 11:38:58

Johns Hopkins team first identified biochemical clue to therapy in brain scans of people with MS Johns Hopkins researchers report the successful use of a form of MRI to identify what appears to be a key biochemical marker for cognitive impairment in the brains of people with multiple sclerosis (MS). In follow-up experiments on mice with a rodent form of MS, researchers were able to use an experimental compound to manipulate that same marker and dramatically improve learning and memory....

2012-07-10 10:30:41

'Molecular grenade' now in clinical trials for advanced cancer Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel -- undetected by normal cells -- through the bloodstream until activated by specific cancer proteins. The drug, made from a weedlike plant, has been shown to destroy cancers and their direct blood supplies, acting like a "molecular grenade," and sparing healthy blood vessels and...

2010-07-02 00:45:30

Progress toward understanding the role of sex hormones in the growth of prostate cancer"”the most common cancer in U.S. men"”has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression. Their results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego. "We hope this model will speed up the process of testing preventive...

2010-06-08 11:48:07

Study could lead to more effective treatment and therapy for prostate cancer as a result of a new molecular imaging technique that targets prostate tumor cells Molecular imaging has a powerful new weapon in the fight against prostate cancer. Research introduced at SNM's 57th Annual Meeting demonstrates how a novel peptide-targeted imaging agent could help clinicians detect a biological process that signals cancer in prostate cells. Information gathered about this process may even...

2009-10-19 17:53:22

Glutamate is to the brain like coffee is to our bodies. A cup of Joe in the morning can wake us, but overloading on caffeine causes the stimulant to work against us. Glutamate is the major excitatory neurotransmitter in a mammal's central nervous system. It is an important component for neuroplasticity, the synaptic communication between neurons. It's also key to learning and memory. But in high concentrations, glutamate becomes toxic-- over-exciting the neurons. Glutamate-induced...

2009-07-13 13:47:08

U.S. scientists say they have developed a prostate cancer homing device that could improve detection and allow the first targeted treatment of the disease. Purdue University researchers said they synthesized a molecule that finds and penetrates prostate cancer cells, and have created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo. Professor Philip Low, who led the research, said a targeted treatment could be much more effective in treating...

a2d028bdcb5c719cc04a98a16dacc6551
2009-07-06 14:45:00

A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease.A team of Purdue University researchers has synthesized a molecule that finds and penetrates prostate cancer cells and has created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.A radioimaging application used for body scans is expected to enter clinical trials this fall, and an optical imaging application used to measure...

2008-09-08 09:00:52

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of a phase 1 dose-escalation clinical study of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). PSMA ADC is an investigational therapy that combines a prostate-cancer antibody with a cancer drug. Unlike traditional chemotherapy, PSMA ADC is designed to deliver the drug selectively to prostate cancer cells by targeting a surface protein, PSMA. The clinical study will include patients with...

2008-09-08 09:00:52

US-based biopharmaceutical company Progenics Pharmaceuticals has initiated a Phase I dose-escalation clinical study of its prostate-specific membrane antigen antibody-drug conjugate. The clinical study will include patients with progressive, metastatic, hormone-refractory disease following prior taxane chemotherapy, and will assess the safety, tolerability and initial clinical activity of prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) followed by the option to...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.